109 / 119
108
Diretrizes AMB
chronic plaque psoriasis: efficacy and safety results from a Phase II/III
randomized controlled study. J Dermatol. 2010 Apr;37(4):299-310.
PubMed PMID: 20507398.
25. Revicki DA, Menter A, Feldman S, Kimel M, Harnam N, Willian MK.
Adalimumab improves health-related quality of life in patients with
moderate to severe plaque psoriasis compared with the United States
general population norms: results from a randomized, controlled Phase
III study. Health Qual Life Outcomes. 2008 Oct 2;6:75. PubMed PMID:
18831744.